Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
Citi’s 17th Annual
BioPharma Conference(1x1 meetings only) Wednesday, September 7, 2022 Boston, Mass.
H.C. Wainwright24th Annual Global Investment Conference Wednesday, September 14, 2022 New York, NY
Dr. Brady’s presentation at the H.C. Wainwright 24th Annual
Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906006042/en/
Investor & Media Contact:
Tel: (857) 383-2409